A New Discovery in Nanomedicine

CelecoxCur
A Safe And Fffective Nanomedicine For
Arthritis
1
2

3

4

LOW DOSE BY IMPROVING SOLUBILITY MAY ANSWER TO MANY PROBLEMS
•

Although a wide range of drugs are available, the successful and
cost effective treatment of inflammatory arthritis is ...
TNF

Phospholipid
PLA2G2A
PLA2G4A
NF-kB

arachidonic acid

IL6

PTGS2

CelecoxCur

PTGS1

IL6

PGH2
?????
PGD2

PGD2

PGD2...
• $1M INVESTED
• $3M NEEDED ( FOR ANALYTICAL
TOOL, cGMP MANUFACTURING,
PRE-CLINICAL, IND, etc)
•
•
•
•
•
•

PROOF OF CONCEPT ------------------ESTABLISHED
R & D---------------------------------------- -MOSTLY ESTABLIS...
Discovery/ Answer to Problem
•
•
•
•
•
•
•
•

CELECOXCUR IS A HYBRID DRUG OF TWO MOLECULES
CELECOXCUR IS WATER SOLUBLE (BI...
MILESTONES
•
•
•
•
•
•

cGMPManufacturing
Animal efficacy: Drug Interactions
IND
Phase I
Phase II
License submission

(1st...
It is not micro
It is Nano
NO OIL, No detergent
IT IS MORE POTENT
LESS TOXIC AND
COST EFFECTIVE
ACT ON MULTIPLE SITE

Nano...
Join us to take this Discovery to clinic

CONTACT
Mewa Singh, PhD
• 609-902-7128
• mewasinghsandhu@hotmail.com
• www.nanom...
Arthritis
Arthritis
Upcoming SlideShare
Loading in...5
×

Arthritis

212

Published on

A new treatment for Arthritis.

www.nanomeda.com

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
212
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
21
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Arthritis

  1. 1. A New Discovery in Nanomedicine CelecoxCur A Safe And Fffective Nanomedicine For Arthritis
  2. 2. 1 2 3 4 LOW DOSE BY IMPROVING SOLUBILITY MAY ANSWER TO MANY PROBLEMS
  3. 3. • Although a wide range of drugs are available, the successful and cost effective treatment of inflammatory arthritis is still a major unmet medical need • Celecoxib is not readily dissolved and dispersed for rapid absorption in the gastrointestinal tract when administered orally • More generally, a need exists for orally deliverable formulations of cyclooxygenase-2 inhibitory drugs of low water solubility including celecoxib. Hence to use high dose to achieve the required efficacy • Do we need to use 400mg of Celecoxib? • Is the drug is a problem or the dosage ? • FDA committee advised doctorsthreat to sale.lowest available doses of Celebrex Patent expired hence a to prescribe the The (200 mg/day) and Bextra (10 mg/day). But how sure are we that these dosages are safe? We know that 400 mg/day of Celebrex causes heart attacks and strokes; can we be sure that 200 mg doesn't? We know that 20 mg/day of Bextra causes heart attacks and strokes; can we be sure that 10 mg doesn't? No, we cannot be sure. More likely, even at these lower recommended dosages, some risk remains.
  4. 4. TNF Phospholipid PLA2G2A PLA2G4A NF-kB arachidonic acid IL6 PTGS2 CelecoxCur PTGS1 IL6 PGH2 ????? PGD2 PGD2 PGD2 PGI2 Inflammation Pain Fever Neoplasia Cytoprotection PGI2 Allergy Aasthma Platelet Aggregation Vasoconstriction
  5. 5. • $1M INVESTED • $3M NEEDED ( FOR ANALYTICAL TOOL, cGMP MANUFACTURING, PRE-CLINICAL, IND, etc)
  6. 6. • • • • • • PROOF OF CONCEPT ------------------ESTABLISHED R & D---------------------------------------- -MOSTLY ESTABLISHED PILOT SCALE MANUFACTURING---- ESTABLISHED IN-VITRO STUDY----------------------- - PRELIMINARY TESTING Pilot scale Production------------------- Established ANIMAL STUDIES----------------------- ON-GOING
  7. 7. Discovery/ Answer to Problem • • • • • • • • CELECOXCUR IS A HYBRID DRUG OF TWO MOLECULES CELECOXCUR IS WATER SOLUBLE (BIOAVAILABLE) CELECOXCUR IS SAFE FOR STOMACH CELECOXCUR IS PATENTED CELECOXCUR IS MORE POTENT CELECOXCUR IS NEW APPROACH CELECOXCUR WATER SOLUBILITY PROBLEM RESOLVED CELECOXCUR LOW DOSE TO ACHIEVE THE SAME RESULTS AS OF 400MG OF CELECOXIB • No SDS, No T-20, No oil, No alcohol, No casein, No cellulose, No PEF and No lipid in CelecoxCur The present invention of CELECOXCUR is directed to a method of treating inflammatory arthritis in a cost effective manner BY LOW DOSE AND LOW COST OF MANUFACTURING. SHOULD BE FAFFER.
  8. 8. MILESTONES • • • • • • cGMPManufacturing Animal efficacy: Drug Interactions IND Phase I Phase II License submission (1st year) (1st year) (2nd year) (2nd year) (3rd year) (3rd and 4th year)
  9. 9. It is not micro It is Nano NO OIL, No detergent IT IS MORE POTENT LESS TOXIC AND COST EFFECTIVE ACT ON MULTIPLE SITE Nanomedicine is The Answer
  10. 10. Join us to take this Discovery to clinic CONTACT Mewa Singh, PhD • 609-902-7128 • mewasinghsandhu@hotmail.com • www.nanomeda.com • www.nanosgroup.com Nanomedicine Is The Future Of Pharma
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.

×